Skip to main content
Clinical Trials/ACTRN12621001213831
ACTRN12621001213831
Recruiting
未知

Does treatment for moderate to severe obstructive sleep apnoea (OSA) improve heart rhythm control in patients following a catheter ablation for Atrial Fibrillation (AF) (SNORE-AF study)

Melbourne Health (Royal Melbourne Hospital)0 sites220 target enrollmentSeptember 10, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Melbourne Health (Royal Melbourne Hospital)
Enrollment
220
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 10, 2021
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Melbourne Health (Royal Melbourne Hospital)

Eligibility Criteria

Inclusion Criteria

  • 1\.Paroxysmal or persistent atrial fibrillation referred for AF ablation. By definition this will include highly symptomatic patients with paroxysmal or persistent AF (ablation is completed as standard of care treatment and not a research study related procedure).
  • 2\.Moderate to severe predominant OSA defined as AHI 15 or greater and a central apnoea index/total apnoea index less than 20 percent (diagnosed by either in lab Polysomnography (PSG) or at home WatchPAT device)
  • 3\.Age 18 years to less than 80 years old
  • 4\.Able and willing to provide informed consent and comply with all testing and requirements.
  • 5\.Willing to use CPAP if randomised to the treatment arm
  • 6\.Willing to defer CPAP treatment by up to 12 months if randomised to the non\-treatment arm.

Exclusion Criteria

  • 1\.History of prior AF ablation procedure
  • 2\.Presence of other significant structural heart disease
  • a.Valvular heart disease ( moderate valvular regurgitation or stenosis)
  • b.Heart failure (Ejection fraction less than 45%; NYHA class 3 or 4\)
  • c.Surgically corrected congenital heart disease (eg ASD repair)
  • d.Hypertrophic cardiomyopathy
  • e.Unstable coronary artery disease
  • f.Severe left atrial enlargement (LA diameter greater than 5\.5cm)
  • 3\.Presence of other major comorbidities
  • a.Renal failure (eGFR less than 50\)

Outcomes

Primary Outcomes

Not specified

Similar Trials